Stock LAVI LAVIPHARM S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lavipharm S.A.

Equities

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E.
Other stock markets
 10:12:12 2024-04-29 am EDT 		5-day change 1st Jan Change
0.854 EUR -0.70% Intraday chart for Lavipharm S.A. +0.83% +7.29%
Feb. 28 Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 7.151 11.24 24.01 29.63 64.46 133.6
Enterprise Value (EV) 1 45.84 50.17 61.48 65.32 83.39 157.7
P/E ratio 5.73 x 2.11 x 11.1 x 17.2 x 9.91 x 71.4 x
Yield - - - - - -
Capitalization / Revenue 0.21 x 0.33 x 0.64 x 0.75 x 1.4 x 2.62 x
EV / Revenue 1.35 x 1.49 x 1.63 x 1.64 x 1.81 x 3.1 x
EV / EBITDA 7.64 x 10.4 x 9.72 x 11.3 x 16.9 x 19.7 x
EV / FCF -17 x -191 x 108 x 24.9 x -2.69 x -33.3 x
FCF Yield -5.89% -0.52% 0.93% 4.01% -37.2% -3%
Price to Book -0.37 x -0.78 x -1.95 x -2.97 x 1.6 x 3.13 x
Nbr of stocks (in thousands) 17,027 17,027 17,027 17,027 167,868 167,868
Reference price 2 0.4200 0.6600 1.410 1.740 0.3840 0.7960
Announcement Date 4/25/19 5/8/20 4/26/21 3/21/22 3/27/23 3/21/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 34.06 33.59 37.64 39.72 46.01 50.93
EBITDA 1 6.002 4.816 6.326 5.761 4.932 8.022
EBIT 1 5.017 3.833 5.235 4.51 4.042 4.388
Operating Margin 14.73% 11.41% 13.91% 11.35% 8.79% 8.62%
Earnings before Tax (EBT) 1 2.861 2.116 3.38 2.747 2.14 3.247
Net income 1 1.249 5.327 2.165 1.723 0.834 1.871
Net margin 3.67% 15.86% 5.75% 4.34% 1.81% 3.67%
EPS 2 0.0734 0.3129 0.1272 0.1012 0.0387 0.0111
Free Cash Flow 1 -2.702 -0.2628 0.5719 2.618 -31.01 -4.736
FCF margin -7.93% -0.78% 1.52% 6.59% -67.4% -9.3%
FCF Conversion (EBITDA) - - 9.04% 45.45% - -
FCF Conversion (Net income) - - 26.41% 151.97% - -
Dividend per Share - - - - - -
Announcement Date 4/25/19 5/8/20 4/26/21 3/21/22 3/27/23 3/21/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 38.7 38.9 37.5 35.7 18.9 24
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 6.446 x 8.085 x 5.923 x 6.195 x 3.838 x 2.997 x
Free Cash Flow 1 -2.7 -0.26 0.57 2.62 -31 -4.74
ROE (net income / shareholders' equity) -6.34% -31.5% -16.3% -16% 5.46% 4.8%
ROA (Net income/ Total Assets) 7.23% 5.25% 6.54% 5.46% 3.03% 2.4%
Assets 1 17.27 101.5 33.1 31.55 27.55 78.1
Book Value Per Share 2 -1.150 -0.8500 -0.7200 -0.5900 0.2400 0.2500
Cash Flow per Share 2 0.1100 0.1000 0.1100 0.1000 0.1100 0.0500
Capex 1 1.03 2.42 1.48 1.92 35.6 4.12
Capex / Sales 3.03% 7.19% 3.92% 4.83% 77.42% 8.08%
Announcement Date 4/25/19 5/8/20 4/26/21 3/21/22 3/27/23 3/21/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
LAVIPHARM S.A. Stock Lavipharm S.A.
+7.29% 154M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.81% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+13.30% 14.09B
CIPLA LIMITED Stock Cipla Limited
+12.97% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+39.74% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAVI Stock
  4. Financials Lavipharm S.A.